Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT 2025

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

Presenter: Patrick W. Serruys

October 28, 2025

Presentation AHA 2024

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

Presenter: Sanjit S Jolly

November 17, 2024

Presentation TCT 2024

CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction

Presenter: Sanjit Jolly

October 29, 2024

Presentation TCT 2022

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Presenter: Yoshinobu Onuma

September 17, 2022

Presentation JIM 2018

The Synergy Stent in High Risk Patients: Why Design Matters

Presenter: Giulio G. Stefanini

February 23, 2018

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Presenter: Dean J. Kereiakes, Pieter C. Smits

October 30, 2016

Presentation TCT 2013

SYNERGY and the EVOLVE Clinical Trial Program: Minimizing the Abluminal Polymer Load while Accelerating Bioresorption

Presenter: Ian Meredith

October 27, 2013

Advertisement

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

The Synergy Stent in High Risk Patients: Why Design Matters

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

SYNERGY and the EVOLVE Clinical Trial Program: Minimizing the Abluminal Polymer Load while Accelerating Bioresorption

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content